Adaptive COVID-19 Treatment Trial (ACTT)
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Listed as NCT04280705, this PHASE3 trial focuses on COVID-19 and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 12 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Oct 2020 — Dec 2020 [monthly]
Completed PHASE3
-
Aug 2020 — Oct 2020 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jun 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
Phase: PHASE2 → PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE2
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .